Hypersensitivity. Severe hepatic impairment, biliary cirrhosis or cholestasis. Severe hypotension. Shock (including cardiogenic shock). Obstruction of the outflow tract of the left ventricle (eg, hypertrophic obstructive cardiomyopathy & high grade aortic stenosis). Haemodynamically unstable heart failure after acute MI. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2
). 2nd & 3rd trimesters of pregnancy.